Trial Profile
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Tetrahydrouridine (Primary)
- Indications Carcinoma; Gastric cancer; Malignant-mesothelioma; Non-small cell lung cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 04 May 2023 Status changed from completed to discontinued (Study terminated due to drug supply issues).
- 16 Feb 2023 Status changed from recruiting to completed.
- 09 Dec 2020 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.